Amid the Twitter war between Bharat Biotech’s Raches Ella and Kolkata researcher Dr Aswadhesh Kumar Singh over Covaxin versus Covishield, Bharat Biotech on Wednesday informed that the company will conduct a phase 4 trial of its vaccine to check the real-world effectiveness of Covaxin. Its phase 3 trial data will be published in July, the company said, after which it will apply for full licensure.
While the Centre has said that these two vaccines can not be compared as they are made differently, researchers have not stopped finding out the answer to the question: which vaccine is better between Covaxin and Covishield. A pre-print study, which is yet to peer-reviewed, has recently claimed that both the vaccines showed a good immune response after two doses. But Serum Institute of India’s Covishield produced more antibodies than Covaxin.
Opposing the reporting of the study, Bharat Biotech’s business development head Dr Raches Ella took to social media and said the study has its limitations.
Dr Aswadhesh Kumar Singh, one of the researchers, pointed to the fact that the “whole country is getting vaccinated even without a preprint phase 3 result — lest forget published one”.
Sleep is often regarded as a luxury in today’s fast-paced world, but scientific research continuously…
Heart disease remains one of the leading causes of death worldwide, and in India, cardiovascular…
Delhi is witnessing a sharp rise in flu cases, particularly Influenza B and H1N1 (commonly…
In early February 2025, a tragic incident occurred in Eluru, Andhra Pradesh, where a 61-year-old…
Holi, the festival of colors, is one of the most vibrant and joyous celebrations in…
In a major development, the U.S. Food and Drug Administration (FDA) has issued recalls for…